UCL Cancer Institute


Glioblastoma Research Group

The aim of our group is to improve outcomes for people diagnosed with glioblastoma. We have a clinical trial programme running together with a translational scientific programme. The clinical trials give patients living with glioblastoma access to novel treatments. Our laboratory research is aimed at improving our mechanistic understanding of therapeutic response and resistance, and provides a rationale for novel therapies.

Paul Mulholland UCL


Group Leader: Dr Paul Mulholland

Consultant in Medical Oncology and Honorary Associate Professor
Email: p.mulholland@ucl.ac.uk

Group members

  • Dr Diego Ottaviani 
    NIHR Academic Clinical Fellow & Specialist Registrar in Medical Oncology
  • Dr Nick Brown
    Clinical Research Fellow & Specialist Registrar in Medical Oncology
  • Dr Ben Kinnersley
    Senior Research Fellow - Senior Computational Biologist


Glioblastoma is the most common and aggressive primary malignant brain tumour. Due to the lack of effective treatment options, Cancer Research UK has included glioblastoma in the category of ‘cancers of substantial unmet need’. Our goal is to improve clinical outcomes for patients with glioblastoma, from pre-clinical development of novel therapies to early and later phase clinical trials.

Clinical trials

We have set up a national programme of clinical trials for patients with glioblastoma. We have recently completed recruitment for the IPI-GLIO trial (ISRCTN84434175) which is a phase II, open label, randomized study of ipilimumab (anti-CTLA monoclonal antibody) and temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. In June 2022 we hope to start recruitment for newly diagnosed patients to have Ipilimumab in a clinical trial - see link for further details (https://www.clinicaltrials.gov/ct2/show/NCT05074992).

Molecular mechanisms in glioblastoma

Alongside clinical trials, we are running a translational programme to improve our understanding of the molecular mechanisms driving glioblastoma response and resistance to treatment. There is emerging evidence that DNA organisation is critical in mediating responses to cancer treatment including chemotherapy and immunotherapy. We are characterising the DNA architecture in glioblastoma and how it can be modified to enhance treatment efficacy.


Lori Houlihan

Lori Houlihan Glioblastoma Fund

In May 2019, UCL's Vice-Provost (Advancement) Lori Houlihan was diagnosed with brain cancer. This Fund will support research that can improve treatments. 

Publications Mulholland Lab

Selected publications

Review our research including results on using immunotherapies prior to surgery, radiotherapy and chemotherapy to improve patient outcomes. 

Intravenous drip Mulholland Lab

Clinical trials

Find out more about our clinical trial programme including open trials and selected completed trials.